Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Japan Chief Sees CAR-T Pricing as “Important Issue” Here Too
September 29, 2017
- VLP Flu Vaccine Enters PIII in North America, Europe: Mitsubishi Tanabe
September 28, 2017
- Sumitomo Dainippon to Slash Manufacturing Jobs via Another Voluntary Redundancy Program
September 28, 2017
- Nichi-Iko Earns Remicade Biosimilar Nod, Picks GI-Savvy Zeria as Copromotion Ally
September 28, 2017
- Japan Approves 1st Rituxan Biosimilar from Sandoz
September 28, 2017
- Fujifilm Takes 6% Stake in Japanese Regenerative Medicine Upstart
September 27, 2017
- FDA Accepts sNDA for Lenvima’s HCC Indication
September 27, 2017
- Medipal’s JCR Deal Aimed at Adding Value to Its Distribution Biz in Japan?
September 27, 2017
- Konica Minolta to Acquire Boston CRO Invicro
September 26, 2017
- Mitsubishi Tanabe Seeks to Block Talion Generic Launches by 3 Makers
September 26, 2017
- Hisamitsu Launches US PII Study for Analgesic Transdermal Patch
September 26, 2017
- Shionogi Initiates Rolling NDA Submission in US for Lusutrombopag
September 26, 2017
- Daiichi Sankyo’s Esaxerenone Hits Primary Endpoint in Patients with Essential Hypertension
September 26, 2017
- Medipal/JCR Want to Establish JV by Year End, Go Global with 8 Products
September 25, 2017
- Pfizer to Discontinue 5 Generics, Transition Period Slated until March 2019
September 25, 2017
- Opdivo Gains Nod for Gastric Cancer; Spinraza Now Available for All SMA Patients
September 25, 2017
- Asahi Kasei Obtains Japan Development Rights for Autologous Cell Therapy Product from Belgium Company
September 25, 2017
- Teva’s Parkinson’s Med Delivers Positive Data in Japan PIII: Takeda
September 22, 2017
- Medipal to Become JCR’s Top Shareholder, Poised to Form JV in US
September 22, 2017
- Yasuhiro Onaka Tapped for Takeda’s Japan Sales Head
September 22, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…